00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
20:37 , Feb 6, 2019 |  BC Innovations  |  Translation in Brief

Testing cognition without bias

Cognetivity Neurosciences Ltd. has developed an image-based cognitive function test that avoids the confounding biases inherent to standard tests and uses artificial intelligence (AI) to interpret the results. The test could enable better detection of...
16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting P2RX7 could help treat autism. In a mouse model of autism, systemic knockout of P2RX7 or a tool compound P2RX7 inhibitor tool decreased social deficits, sensorimotor coordination impairment and...
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
00:37 , Jan 23, 2019 |  BC Extra  |  Preclinical News

Neurofilament light chain could predict familial Alzheimer's progression

Researchers showed that measuring neurofilament light (NEFL; NF-L) chain could predict progression in familial Alzheimer's disease, suggesting the protein could be used as a biomarker and for developing diagnostics for the disease. In a paper...
19:38 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest adoptive transfer, or promoting the survival, of IgA-positive plasmablasts and plasma cells could help treat MS. In fecal samples from relapsing-remitting MS (RRMS) patients, counts...
19:37 , Jan 16, 2019 |  BC Innovations  |  Translation in Brief

Promoting gut plasmablasts for MS

Researchers from the University of Toronto and colleagues have linked the gut-brain axis to multiple sclerosis by showing gut plasmablasts and plasma cells suppress CNS inflammation during active MS, and suggested therapies that promote the...
17:10 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest agonizing VSIG4 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an agonist mAb against VSIG4 decreased disease severity and infiltration of proinflammatory...
04:29 , Jan 11, 2019 |  BC Innovations  |  Product R&D

Biomarkers’ road less traveled

FDA’s draft guidance on biomarker qualification provides welcome codification of the regulatory path. But the amount of data required may remain beyond the reach of most companies, strengthening the importance of consortia. The guidance ,...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...